Clinical trials: Phase 1
Healthy, Overweight
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.
This is a Phase 1, first-in-human (FIH), randomized, double-blind, placebo-controlled, combined single (Part A) multiple (Part B, C) ascending dose, phase 1 study to investigate the safety, tolerability and pharmacokinetic and…
- Trial name
- NCT06309667
- Testing
- PG-102(MG12)
- Where
- South Korea
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- ProGen. Co., Ltd.
Healthy
A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants.
The purpose of this study is to learn how different preparations of sisunatovir are taken up into the blood when taken on an empty stomach or with a meal in healthy adults.
- Trial name
- NCT05994963
- Testing
- sisunatovir
- Where
- Belgium
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
UP-818-CC Injection in Healthy Chinese Subjects
The objectives of this study are to evaluate the safety, tolerability and pharmacokinetic characteristics in healthy Chinese volunteers after single and multiple dose of intravenous infusion of UP-818-CC.
- Trial name
- UP-818-CC (NCT07355621)
- Testing
- UP-818-CC injection
- Where
- China
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
Chronic Hepatitis C
The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single \& Multiple Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in Healthy Adult Subjects
- Trial name
- HEC110114 (NCT03903081)
- Testing
- HEC110114 tablet
- Where
- China
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Pharmacokinetics
Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation
RhuDex® (code number AV1142742) is a novel, orally bioavailable, low molecular weight modulator of co-stimulation of T lymphocytes.
- Trial name
- NCT00704119
- Testing
- RhuDex®
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- MediGene
Healthy Volunteers
A First-in-Human Single and Multiple Ascending Dose Study of MT-701
First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.
- Trial name
- NCT07396909
- Testing
- MT-701
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Mirador Therapeutics, Inc.
Renal Impairment
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AZD5462 in participants with impaired renal function.
- Trial name
- GLITTER (NCT06661733)
- Testing
- AZD5462
- Where
- Bulgaria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants
The purpose of this study is to evaluate the effect of CC-99677 coadministration on the pharmacokinetics (PK) of an oral contraceptive (OC).
- Trial name
- NCT04718636
- Testing
- Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent), CC-99677
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Celgene
Influenza
Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly
Probiotics are viable commensal microorganisms that promote the establishment of beneficial microflora. Animal and human studies demonstrate that probiotics can enhance body's immune response to stimuli.
- Trial name
- NCT01304771
- Testing
- Synbiotic AKSB
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Parkinson's Disease
Phase I, KM-819 in Healthy Subjects for Parkinson's Disease
This first in human, single-center, randomized, placebo-controlled, double blind, sequential group Phase 1 study in healthy subjects will be conducted to evaluate the safety, tolerability, PK, and PD following the escalation of…
- Trial name
- NCT03022799
- Testing
- KM-819
- Where
- South Korea
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Kainos Medicine Inc.
Healthy Subjects
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers
This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.
- Trial name
- NCT05236998
- Testing
- SID1903 (FDC), Dapagliflozin and Sitagliptin
- Where
- South Korea
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Autoimmune Diseases
A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)
This is a phase 1 study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and in participants with autoimmune disease(s).
- Trial name
- NCT05418101
- Testing
- VIS171
- Where
- 10 sites in Bulgaria, Germany and 3 more
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Ulcerative Colitis
TUDCA as a Therapy for Ulcerative Colitis (UC)
This is a Phase I open label study examining the efficacy and safety of TUDCA (tauroursodeoxycholic acid) in ulcerative colitis treatment.
- Trial name
- TUDCA (NCT04114292)
- Testing
- Tauroursoursodeoxycholic acid, brand name Tudcabil
- Where
- 3 sites in United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
COVID-19, SARS-CoV-2 Infection
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA COVID-19 Vaccine.
The objective of this study is to evaluate the safety, tolerability and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with mRNA COVID-19 vaccine.
- Trial name
- NCT05043311
- Testing
- SCTV01C
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Malaria
Trial to Evaluate CIS43LS in Healthy Adults
Background: People get malaria when they are bitten by an infected mosquito. Malaria can be serious and sometimes deadly. Although there are medicines to treat malaria, there is no vaccine that fully prevents infection.
- Trial name
- NCT04206332
- Testing
- VRC-MALMAB0100-00-AB, Plasmodium falciparum (P. falciparum) sporozoite challenge
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatic Impairment, Healthy
Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function
The purpose of this study is to evaluate how much of the study drug SSP-004184 (SPD602) is absorbed by the body and how long it takes to be eliminated from the body in healthy subjects and subjects with mild, moderate, and severe…
- Trial name
- NCT01732263
- Testing
- SSP-004184
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Shire
Gout, Hyperuricemia
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of ABP-671 administered orally in healthy volunteers.
- Trial name
- NCT03906006
- Testing
- ABP-671
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Atom Therapeutics Co., Ltd
Systemic Lupus Erythematosus, Arthritic Psoriasis
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165…
- Conditions
- Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases
- Trial name
- NCT03254784
- Testing
- BMS-986165 Capsule, BMS-986165 Tablet
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Pharmacokinetics, Pharmacodynamics
A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects
The purpose of this study is to explore the safety (including the effect on cardiac intervals), tolerability, the effects on the Central Nervous System (CNS), as well as the CNS side effect profile of single ascending doses of…
- Conditions
- Pharmacokinetics, Pharmacodynamics, Healthy Subjects, Safety
- Trial name
- NCT01815684
- Testing
- ASP3652
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy Adults
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
A Phase 1, Open-label, One-sequence Crossover Study to Investigate the Effect of a Breast Cancer Resistance Protein Inhibitor on the Single-dose Pharmacokinetics of Adagrasib in Healthy Adult Subjects
- Trial name
- NCT05924152
- Testing
- Adagrasib, Eltrombopag + adagrasib
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.